Introduction
Despite substantial progress in treatment of newly diagnosed childhood acute lymphoblastic leukaemia (ALL) with risktailored protocols, about 20-30% of children eventually relapses. 1, 2 Recent clinical studies in ALL demonstrated the clinical relevance of minimal residual disease (MRD) detection in the follow-up of the disease. 3, 4 The precise evaluation of MRD levels during and after the course of the disease is important to identify patients with higher risk of recurrence that will therefore enter different risk-adapted therapeutic protocols, 3, 4 and it might help in giving a new definition of molecular remission in ALL. 5, 6 Quantitative MRD data in the majority of haematological malignancies can be obtained by real-time quantitative PCR (RQ-PCR) using immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements 7, 8 as PCR targets. Ig and TCR rearrangements are characterized by a unique clone-specific junctional regions that can be considered as a leukaemia clone-specific fingerprint. [9] [10] [11] At diagnosis these Ig and TCR rearrangements are routinely detectable in about 90% of precursor-B-ALL and 95% of T-ALL patients by PCR; 9,12,13 a sensitivity of 10
À4
-10 À6 can be reached using these molecular targets in quantitative MRD experiments. 7, 8 Moreover, Ig/TCR-based clonality studies might provide an instrument to investigate the course of the disease in children with ALL. 14, 15 However, clonal evolution of Ig and TCR gene rearrangements due to continuing and secondary recombination events throughout the disease course could limit the effectiveness of V(D)J junctional sequences as targets in detecting MRD, since it may lead to false-negative results. 16, 17 The high-resolution PCR fragment analysis using GeneScan technique (PCR-GSA) is an accurate procedure in determining the size of PCR products and in discriminating between polyclonal and clonal DNA banding profiles. [18] [19] [20] In this study, we carried out complete GeneScan and sequence analyses of every Ig and TCR gene rearrangement independently found at diagnosis and relapse in a homogeneous series of 53 childhood precursor-B-ALL patients, in order to get detailed information on the evolution and the stability of potentially useful MRD-PCR targets.
Materials and methods

Patients and samples
Our study included 53 relapsed patients, presenting with precursor-B-ALL between 1989 and 2002; this concerned 19 females and 34 males with a mean age of 5.82 years (range 0.58-14.33 years). Diagnosis of precursor-B-ALL was made according to standard cytomorphology, cytochemistry and immunophenotypic criteria. 21, 22 The selection of patients was based on the availability of cryopreserved bone marrow (BM) samples at initial diagnosis and at first relapse. Two patients, suffering from BM relapse more than once, were studied at two and three subsequent leukaemia relapses, respectively. DNA was extracted from BM mononuclear cells (MNCs) after FicollPaque centrifugation (density 1.077 g/cm 3 ; Pharmacia, Uppsala, Sweden), using either standard techniques (phenol-chloroform organic extraction) or a commercial kit (Puregene DNA isolation kit, Gentra Systems, Minneapolis, MN, USA). The integrity of each DNA sample was checked amplifying albumin.
Comparative immunophenotyping analysis
Immunophenotyping was performed using a direct immunofluorescence technique on MNCs obtained at diagnosis and relapse from BM. Monoclonal antibodies directly conjugated with fluorescein isothiocyanate, phycoerythrin and the phycoerythrin-cyanine 5 fluorochrome tandem conjugate were combined in each tube as previously reported. 21, 23 The analyses were carried out in an Epics XL (Beckman Coulter, Miami, FL, USA) flow cytometer, and leukaemias were classified according to previously reported criteria. 24 Immunophenotyping of samples at diagnosis allowed the identification of one (2%) pre pre-B, 30 (57%) common and 22 (41%) pre-B leukaemias. Comparative immunophenotype analysis between diagnosis and first relapse showed intralineage shifts of antigen expression in 28% (15/53) of cases, in particular, switches concerned 23% (7/30) of common and 36% (8/22) of pre-B leukaemias.
PCR amplification and GeneScan/heteroduplex clonality analyses
Each diagnostic and relapse BM sample was independently screened for both Ig and TCR gene rearrangements, as previously described. 9, 25 Briefly, 28 primer pairs were used to amplify IGH (five VH-JH and seven DH-JH), IGK (four Vk-kde and Irss-kde), TCRG (three Vg-Jg1.3/2.3 and three Vg-Jg1.1/2.1) and TCRD (complete Vd1-Jd1, Vd2-Jd1 and Dd2-Jd1, incomplete Vd2-Dd3 and Dd2-Dd3) recombinations. GeneScan analysis was performed using fluorescent reverse primers labelled at their 5 0 end with 6-carboxyfluorescein (FAM). All reactions were carried out in a final volume of 50 ml with 100 ng of DNA sample, 200 nM of dNTPs, 12 pmol of each primer and 2 U of Taq polymerase. Primer sequences and PCR conditions were previously published. 7, 9 Each PCR experiment included an appropriate positive clonal control, a polyclonal control (MNC DNA, MNC) and a nontemplate negative control. 9 Aliquots of 1:25 diluted PCR products (1.5 ml) were mixed with 13.5 ml formamide, and 1 ml of the internal size standard (Genescan-500 and Genescan-1000, Applied Biosystem, Foster City, CA, USA) was included for precise determination of the length of the amplicons. After denaturation for 10 min at 941C, the products were separated on POP-4 polymer (Applied Biosystem, Foster City, CA, USA) and analysed by 310 GeneScan 3.1 software (Applied Biosystems Foster City, CA, USA). Scanning results of fluorescence-dye-labelled PCR products by GSA were interpreted as follows: one or two striking peaks indicated a dominant leukaemic clone, while polyclonality was characterized by a number of peaks arranged in a normal distribution. 20, [26] [27] [28] A sensitivity test was also performed, diluting diagnostic or relapse samples in MNC DNA: clonal rearrangements of a characteristic size identified at presentation and relapse were detectable at a dilution of 1 Â 10 À3 in more than 50% of cases, and at a level of 5 Â 10 À3 in 89% of samples. Clonality identification was also performed by means of traditional heteroduplex analysis as described:
9,29-31 each positive PCR product was denatured at 951C for 5 min and rapidly cooled to 41C to induce duplex formation, then loaded on 12% nondenaturing polyacrylamide gel in 1 Â Tris-borate-EDTA buffer (TBE) at 10 mA and 41C, or 12.5% nondenaturing polyacrylamide minigel (PhastGelt, Pharmacia Biotech, Uppsala, Sweden), visualized by ethidium bromide and silver staining, respectively. 31 Heteroduplex analysis enables discrimination between PCR products derived from clonal and polyclonal lymphoid cell populations, based on the presence of homoduplexes (PCR products with identical junctional regions) or a smear of heteroduplexes (derived from PCR products with heterogeneous junctional regions), respectively. 13, [29] [30] [31] In order to compare each diagnostic and relapse patient sample, PCR products were mixed together (1:1) and subjected to mixed heteroduplex analysis. 13, 32 Figure 1 gives some examples of the application of PCR-GSA and heteroduplex analysis in precursor-B-ALL patients.
Sequencing analysis
Each clonal PCR product independently found either at diagnosis or at relapse was sequenced. Fluorescence sequencing was performed using the BigDye Terminator Cycle Sequencing Ready Reaction Kit on ABI Prism 310 (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's guidelines. Homoduplex PCR products were directly sequenced, whereas heteroduplex ones were either excised and eluted from polyacrylamide gel or cloned into pCRt 2.1-TOPO vector (TOPO TA Cloning, Invitrogen, Carlsbad, CA, USA) in order to allow the identification of the different alleles. For each DNA sample, five to 10 randomly chosen clones were sequenced. Sequences of junctional regions (N regions) were determined by comparison to germline sequences and to known human sequences in databases (www.mcr-cpe.cam.ac.uk/imt-doc and www.ncbi.nlm.nih.gov/BLAST).
Statistical analysis
Statistical analysis using the w 2 test on a 2 Â 2 table was performed to compare the frequencies of particular Ig/TCR gene rearrangements between different precursor-B-ALL patients' subgroups. SAS package (SAS Institute, Cary, NC, USA) was used for computation, and P-values less than or equal to 0.05 were considered statistically significant.
Results
GeneScan and heteroduplex PCR analyses
The clonality pattern at diagnosis and relapse of 53 precursor-B-ALL patients was independently studied by PCR-GSA, conventional PCR heteroduplex and sequence analyses. At diagnosis, all 53 (100%) patients presented at least one Ig/TCR gene rearrangement, with an average of four clonal PCR targets per patient. At diagnosis, IGH, IGK, TCRD and TCRG rearrangements were found in 44 (83%), 22 (42%), 33 (62%) and 33 (62%) precursor-B-ALL patients, respectively. A total number of 218 clonal PCR targets were identified and analysed at diagnosis. This concerned 86 IGH (70 complete VH-JH, 16 incomplete DH-JH), 31 IGK (25 Vk-kde, 6 Irss-kde), 49 incomplete TCRD and 52 TCRG gene rearrangements (Table 1) .
Stability of Ig and TCR gene rearrangements
In all, 23 patients (43%) maintained at relapse all the rearrangements identified at diagnosis, while 50 (94%) and 40 (75%) cases presented, respectively, at least one and two conserved PCR clonal targets. Only three patients (6%) had fully different Ig/TCR gene rearrangement patterns at the two phases of the disease.
Concerning the clonal rearrangements, 154 out of 218 (71%) rearrangements amplified at diagnosis were conserved at subsequent relapse: in particular, 60 out of 86 IGH (70%), 22 out of 31 IGK (71%), 33 out of 49 TCRD (67%) and 39 out of 52 TCRG (75%) gene rearrangements were maintained (more details are shown in Table 1 ).
The stability profile of Ig and TCR rearrangements, as a result of the comparison between diagnosis and relapse of each patient, is schematized in Figure 2 .
Analysis of Ig gene rearrangements
The stability of IGH gene rearrangements was 70%, with 60 out of 86 clonal PCR targets maintained identical at relapse: in Comparison between heteroduplex and GeneScan PCR analyses. Polyacrylamide silver-stained Minigels 12.5% (a, c, e) and GeneScan electropherograms from ABI 310 Genetic Analyzer (b, d, f) are represented. The size of each product (in base pairs) is displayed on the x-axis with its relative fluorescence intensity on the y-axis. The first lane in the gels and the red plot in the electropherograms represent the molecular weight marker and the size standard, respectively. In each case, the same clonality pattern was obtained both by mixed heteroduplex and GeneScan analysis. (a, b) In patient #3C, diagnosis and relapse samples showed two identical PCR amplified rearranged alleles (VH3-JH) also in mixed heteroduplex analysis, as confirmed by GeneScan peaks. Patient #28 presented identical clonal VH3-JH PCR products at diagnosis and relapse, while patient #61 showed differences between the two phases of the disease, as shown both by mixed heteroduplex and GeneScan analysis. (c, d) The analysis of IGK rearrangements showed that diagnosis and relapse of patient #1G (V k III-kde) had different clonal PCR products, while both in patient #5D and in #7E completely identical VkIII PCR products were found at the two phases of the disease. The formation of additional heteroduplex bands in the mix sample of patient #1G confirmed the diversity of the rearrangements at diagnosis and relapse. (e, f) Patient #91 showed two fully identical Vd2-Dd3 amplified targets at diagnosis and relapse; identical clonal Vd2-Dd3 PCR products were found in patient #1E, while different clonal ones were identified in patient #1G at diagnosis and relapse, as revealed by the presence of additional heteroduplex bands. M: molecular weight marker; D: diagnosis; R: relapse; MIX: sample obtained by mixing of diagnosis and relapse PCR products. With regard to the 44 patients characterized by IGH clonal rearrangements at diagnosis, 34 (83%) out of 41 with VH-JH clonal targets and eight (80%) out of 10 with DH-JH clonal targets at diagnosis relapsed with at least one stable rearrangement. Moreover, 27 patients (66%) conserved all their complete IGH rearrangements, while six cases (60%) maintained all their incomplete IGH rearrangements (Table 1) .
The clonality pattern of 18 relapsed patients showed differences (loss, change, gain of rearrangements or a combination of these events) compared to the original IGH clonal profile identified at diagnosis; 10 cases showed loss of IGH clonal targets, seven patients gained at relapse new rearrangements not previously detected at diagnosis, six patients showed some changes in rearrangements already present at diagnosis.
A different VH3 allele added to a preserved N-JH4 joining was observed in patient #73; other two patients (#7F, #69) presented two VH3 PCR products at diagnosis and relapsed with one different VH3 rearrangement, which conserved the same N-DH-N-JH join, suggesting a typical VH replacement. In other three patients (#1A, #25, #61) sequence analysis of IGH rearrangements revealed possibly new secondary rearrangements.
IGK gene rearrangements had a stability of 71%, with 22 out of 31 conserved clonal PCR targets at relapse (18/25, 72% Vkkde and 4/6, 67% Irss-kde).
Vk-kde gene rearrangements were present in 19/53 (36%) patients, and at least one of these targets was preserved in 89% of the cases while 14 (74%) patients presented all diagnostic Vk-kde rearrangements at relapse. Irss gene rearrangement, characterizing 11% of the patients at diagnosis, was preserved at relapse in 67% of cases (Table 1) .
In 11 patients, we found differences (loss, change, gain of rearrangements or a combination of these events) between the clonality pattern at diagnosis and relapse. Loss of IGK gene rearrangements regarded six patients, whereas six patients acquired new clonal PCR targets at relapse. Modifications were identified in only one patient (#1G): he presented VkI, VkIII and Irss clonal PCR targets at diagnosis. At relapse he lost VkI-kde gene rearrangement and presented new VkIII and Irss both with different junctional regions.
Analysis of TCR gene rearrangements
The stability of TCRD rearrangements was 67%, with 33 out of 49 diagnostic clonal targets found identical at relapse of the disease. TCRD clonal targets at diagnosis were represented only by incomplete rearrangements (Vd2-Dd3, Dd2-Dd3); at least one stable clonal target was found at relapse in 76% of the patients presenting TCRD rearrangements at diagnosis, while 19 (56%) patients maintained all their TCRD rearrangements (Table 1) .
In all, 18 patients presented differences between diagnostic and relapse TCRD gene rearrangements; nine cases showed loss of TCRD clonal targets, eight patients gained at relapse new rearrangements not previously detected at diagnosis. In three cases (#3D, #1G, #55) sequence comparison revealed differences in the junctional regions of Vd2-Dd3 target, indicating Clonality profiles at diagnosis and relapse G Germano et al possible secondary rearrangements. Other two patients (#3C, #23) relapsed with only one out of the two original Vd2-Dd3 rearrangements found at diagnosis. In case #81, relapse was characterized by two Vd2-Dd3 targets, one of which was identical to the clonal Vd2-Dd3 target detected at diagnosis. GeneScan analysis allowed also the interpretation of TCRD gene rearrangement pattern in patient #51, which was characterized by a series of dominant peaks for Vd2-Dd3 gene rearrangement at diagnosis and only two dominant peaks at relapse: most likely, the two peaks at relapse were already present within the peak profile of diagnostic sample. The stability of TCRG rearrangements was 75% (39/52 stable rearrangements). In all, 27 patients (82%) showing TCRG gene rearrangements at diagnosis had at least one stable target at relapse, while 17 (52%) maintained all diagnostic TCRG targets (Table 1) .
On the other hand, some diagnostic TCRG trait fragments differed at relapse in 21 patients. In 11 cases TCRG clonal targets were lost, and in 16 patients new rearrangements undetected at diagnosis were gained at relapse. None of the patients showed modifications in the sequence of junctional regions of rearrangements found both at diagnosis and at relapse.
New rearrangements at relapse
The independent analysis of diagnostic and relapse samples allowed the identification of new clonal PCR targets in 24 patients at relapse (45%): this concerned 13 IGH, 8 IGK, 14 TCRD and 23 TCRG gene rearrangements. To verify whether these clonal targets were already present at diagnosis, patientspecific forward primers were designed complementary to the sequences of relapse junctional regions and tested in diagnostic samples by RQ-PCR. 7, 8 All IGH and IGK gene rearrangements were tested for presence at diagnosis. Only two IGK gene rearrangements (both VkII) were detected in the diagnostic samples of two patients (cases #56 and #76), with a positivity less than 10 À4 and 10
À5
, respectively, indicating that they were characteristic of subclones already present at diagnosis. Interestingly, none of the tested new IGH rearrangements was found in diagnostic samples, with a sensitivity of 1 Â 10
.
Discussion
At present, relapse remains the most important obstacle to overcome in childhood leukaemia.
1,2,33 The investigation of clonality profiles by means of Ig/TCR gene rearrangements is a very powerful tool for understanding whether relapse represents the reoccurrence of the original leukaemic clone/s or a secondary malignancy. 17, [34] [35] [36] [37] [38] [39] [40] [41] [42] The existence of at least one conserved rearranged clonal target confirms that relapse is probably related to the diagnostic clone.
Although Southern blot analysis is considered to be the gold standard for detection of clonal Ig and TCR gene rearrangements, previous studies 12, 13, 25, 34 demonstrated a high concordance (490%) between Southern blot and heteroduplex PCR analysis. In this Ig/TCR clonality study, we used an exclusively PCR-based strategy, which is the method routinely employed for MRD target detection within International BFM Study Group. 3, 9 A molecular relation between diagnosis and relapse was established in 50 of the 53 childhood precursor-B-ALL patients. In 43% of patients all clonal PCR targets identified at diagnosis were detected also at relapse. In only three patients (cases #1A, #1C and #61, relapsed after 32, 46 and 61 months after diagnosis) the Ig/TCR gene rearrangements profile at diagnosis and relapse were completely different (Figure 2) , with unrelated junctional region sequences. Eventually, these three cases of leukaemia relapse may turn out to represent new malignancies.
In our extensive molecular study, we did not find a correlation between remission duration and clonality profile of the patients, Only incomplete Vd2-Dd3, Dd2-Dd3.
Clonality profiles at diagnosis and relapse G Germano et al and this is in line with previous similar reports. 17 Case #9D presented three consecutive relapses and the Ig/TCR clonality profile was determined for each relapse. Interestingly, at diagnosis he showed three clonal PCR targets (VH3-JH5, Vg3-Jg1.3/2.3, Vg8-Jg1.1/2.1), all preserved both at first and second relapse; a new Vd2-Dd3 gene rearrangement appeared at first relapse, being conserved at second one. At six months after allogeneic BM transplantation he relapsed for the third time and all clonal PCR targets previously identified were lost. The analysis of Ig/TCR gene rearrangements at third relapse showed only a new Vg9-Jg1.3/2.3 clonal PCR target. Consequently, it seems that the third relapse, being completely different from the previous phases of the disease, might represent a new leukaemia. Further studies such as comparative Southern blot analysis and/or identification of other gene rearrangements (TCRB, TCRA, IGL, fusion genes) should be performed in order to demonstrate real secondary malignancies.
GeneScan analysis employed in this study for clonality assessment in ALL demonstrated to be effective: the sensitivity of 5 Â 10 À3 is highly satisfactory at diagnosis or at relapse; in addition, the automatic size determination was shown to be a valuable tool for interpreting clonal profiles, since resolution of PCR products within a narrow size range is inefficient by conventional polyacrylamide gel electrophoresis; in fact, exact assessment with discrimination of one base pair is only possible using GeneScan analysis. 28, 43 We achieved a very good agreement in the results of the two techniques (Figure 1) , and GeneScan analysis has the advantage that allows a direct comparison of Ig/TCR gene rearrangements, skipping the mixing of PCR products followed by heteroduplex analysis. 32 Therefore, GeneScan analysis could represent a valid alternative for rapid discrimination between identical or different clonal PCR products at diagnosis and at relapse. Recent studies 3, 4 demonstrated that early response to treatment, measured by MRD detection exploiting Ig/TCR gene rearrangements, is one of the most relevant and reliable prognostic factors in ALL; therefore, the choice of suitable and stable clonal PCR targets is a crucial issue in MRD monitoring.
Recently, Szczepanski et al 17 reported a particularly high stability for IGK rearrangements, suggesting the preferential choice of these clonal PCR targets for MRD strategy. 44 The results of our detailed PCR-GSA and sequencing analysis of Ig/TCR gene rearrangement profile add a contribution for selecting PCR targets for MRD detection in childhood precursor-B-ALL. Ig/TCR clonal targets for MRD detection were identified in all patients (100%), with 71% of these targets being preserved at relapse. The stability of Ig/TCR gene rearrangements was approximately 70% (IGH 70%, IGK 71%, TCRD 67%, TCRG 75%) with no significant difference among the different clonal PCR targets (Table 1) . Consequently, this suggests that there is no 'preferential' MRD-PCR target and that all targets may be equally useful for MRD monitoring.
We therefore propose that the selection of MRD-PCR targets should be based mainly on the sensitivity tests in RQ-PCR experiments: each target with a minimum sensitivity of 10
À43
should represent the first choice for evaluation of MRD in precursor-B-ALL patients. Although the use of all available and sensitive PCR clonal targets would be the best strategy for MRD detection in ALL patients, this might be unrealistic especially for large routine diagnostic laboratories; therefore, the widely used combination of two MRD-PCR targets could be acceptable to reduce false-negative results. 3, 4, 11, 17 It has been reported that MRD detection using TCRG gene rearrangements in precursor-B-ALL patients often results in low sensitivities due to nonspecific amplification of rearrangements in normal Tlymphocytes, 45 and this feature generally limits the applicability of this target for MRD detection. Consequently, TCRG targets should be used when samples do not present any nonspecific amplification in reproducible RQ-PCR experiments. Furthermore, in approximately 10% of our precursor-B-ALL patients we observed the occurrence of ongoing and secondary gene rearrangements involving Ig/TCR loci. As regards IGH gene rearrangements, patient-specific primers should be designed complementary to DH-N-JH junctional regions in order to minimize false-negative results due to clonal evolution: in two of our cases (#7F, #69) primers designed on DH-JH stems might have allowed the detection of relapse.
Detailed sequencing analysis of Ig/TCR gene rearrangements at diagnosis and relapse is the most reliable way to understand how rearrangements persist or change/evolve during the course of the disease. In order to assess if new rearrangements observed at relapse represented minor clones already present albeit at very low levels at diagnosis, we performed a very sensitive quantitative PCR approach, but the overall stability of IGH and IGK gene rearrangements was not affected by the results. The new rearrangements found at relapse had probably developed during the course of the disease. Our findings suggest that cells from the original clone/s can remain dormant for long periods of time. The mechanisms responsible for this dormancy are not known, but probably they involve either an ability of the clonal cells to remain out of cell cycle, or the inability of host immune surveillance to eradicate minimal residual leukaemia, or a combination of the two. 40 Another hypothesis is that some cells escape the activity of chemotherapy, remaining protected in particular sites and resulting therefore undetectable in bone marrow. 46 It has also been reported that chemotherapy could eliminate an overt leukaemic subclone that dominates at diagnosis, but may fail to eradicate a 'preleukaemic' clone that persist after cessation of therapy: the proliferative stress during the regenerative rebound may convert a 'preleukaemic' cell into a new leukaemic clone. 47 In conclusion, our results show that none of the clonal Ig and TCR gene rearrangements we tested stands out for a striking stability. Clonal evolution phenomena and ongoing secondary rearrangement processes may determine changes in clonality patterns. The use of two sensitive Ig/TCR targets in clinical setting is a good compromise between the applicability of the method in large routine analyses and the stability of the clonal targets; in particular, when the informative time points used for clinical choices are within the first 3 months of therapy. It remains to be demonstrated whether the kinetic of clearance of the clones at early time points is different for targets which later will demonstrate their instability.
